To your knowledge, the toxicities seen in our patients never have been described with vemurafenib in the medical literature, resulting in the concern how the preceding anti-PD-1 may have performed a job
To your knowledge, the toxicities seen in our patients never have been described with vemurafenib in the medical literature, resulting in the concern how the preceding anti-PD-1 may have performed a job. There's been significant fascination with combining BRAF inhibitors with immune-based therapies, tempered by a problem that combination or sequential therapy might augment toxicities. rechallenge. Additional investigation from the immune system response during sequences or mix of melanoma therapeutics MC-Val-Cit-PAB-rifabutin is certainly warranted. Furthermore, clinicians should maintain a higher index of suspicion for these toxicities when vemurafenib can be administered pursuing an anti-PD-1 agent. Keywords:Melanoma, vemurafenib, anti-PD-1, immunotherapy == Background == Metastatic melanoma can be historically connected with limited treatment plans and poor results. In 2011, two real estate agents were authorized for the treating advanced melanoma. Vemurafenib, a…